Determining the optimal second-line approach in patients with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed either on 1 or 2 lines of therapy and who had ...

Pharmacy is under pressure from every direction — shrinking reimbursements, 340B headwinds, rising drug costs, and a workforce stretched thin. And yet the pharmacy leaders living inside that pressure ...

A death cross forms when a stock’s 50-day moving average crosses below its 200-day moving average, signaling a potential downtrend. Right now, Bristol Myers Squibb (NYSE: BMY), FedEx (NYSE: FDX), and ...

The US approval is supported by Phase III SWOG 1826 data assessing Opdivo plus AVD.

If you buy through our links, we may earn a commission. Our process 'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison ...

If you buy through our links, we may earn a commission. Our process 'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison ...

Bristol Myers Squibb received expanded approvals for its Opdivo cancer drug to treat classical Hodgkin Lymphoma from regulators in the U.S. and the European Union. The pharmaceutical company said ...

Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) in advanced-stage classical Hodgkin lymphoma. CA209-8UT randomized 994 ...

The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s BMY Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of ...

The Treasury Department will take over the management of student loans whose borrowers are in default, according to a new agreement announced Thursday. Borrowers do not need to do anything ...

Makeup by Mario was founded by celebrity makeup artist Mario Dedivanovic, perhaps most known for working with Kim Kardashian, six years ago in 2020.

A bill to fund the Department of Homeland Security has failed to advance in the Senate amid growing concerns about long lines to get through screening at some of the ...